# Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy

> **NCT01329354** · PHASE2 · UNKNOWN · sponsor: **Clinica Universidad de Navarra, Universidad de Navarra** · enrollment: 38 (estimated)

## Conditions studied

- Follicular Lymphoma
- Follicular Non-Hodgkin´s Lymphoma
- Autologous Effector Lymphocytes

## Interventions

- **BIOLOGICAL:** Autologous effector lymphocytes expanded ex-vivo

## Key facts

- **NCT ID:** NCT01329354
- **Lead sponsor:** Clinica Universidad de Navarra, Universidad de Navarra
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-03
- **Primary completion:** 2019-11
- **Final completion:** 2019-11
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2017-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01329354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01329354, "Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01329354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*